Companies Dominating the Mucopolysaccharidosis Treatment Market
- Shire Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sanofi Genzyme
- BioMarin Pharmaceutical
- Ultragenyx Pharmaceutical
- Regenxbio
- Abeona Therapeutics
- Sangamo Therapeutics
- Denali Therapeutics
- Lysogene
- ArmaGen
Browse Key Market Insights with Data Illustration:
In the News
- Beyfortus™ is a novel, long-acting RSV pre-exposure prophylaxis (pre-EP) monoclonal antibody developed by Sanofi and Genzyme. The vaccine was found to be safe and effective in preventing RSV infection in infants from 6 weeks to 5 months of age. The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend routine use of Beyfortus™ for all infants in the United States.
- Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment. Qunol® is a leading brand of nicotinamide riboside (NR) supplements, which are naturally produced in the body and play a role in cellular energy production.
